Cancer, Malaria & TB Vaccines


Malaria continues to claim an estimated 2 to 3 million lives annually and to account for untold morbidity in the approximately 300 to 500 million people infected annually. Malaria is considered a re-emerging disease, due largely to the spread of drug-resistant parasite strains, decay of health-care infrastructure and difficulties in implementing and maintaining vector control programs in many developing countries. Four species of protozoan parasites cause malaria in humans: Plasmodium falciparum, P. vivax, P. malariae, and P. ovale. P. falciparum is responsible for the majority of deaths and most of the severe forms of disease, including cerebral malaria. 2 billion people latently infected with M. tuberculosis 5-10% infected people progress to disease 9 million new TB cases each year 1.5 million TB deaths each year Equivalent to 20 passenger aircraft crashes each day. TB is transmitted by adults with cavitatory disease HIV infected people carry greater burden of disease. Highest risk of progression from TB infection to active disease, and worst TB morbidity and mortality, compared to older children and adults.



 


  • Cancer immunoprevention
  • Therapeutic cancer vaccines
  • Preventive cancer vaccines
  • Preventive cancer vaccines
  • Malaria Vaccines for Pregnants and Newborns
  • Novel Methods in TB vaccination
  • Tumour antigen

Related Conference of Cancer, Malaria & TB Vaccines

May 30-31, 2024

World congress on Immunology and Virology Diseases

Vienna, Austria
August 01-02, 2024

44th Global Summit and Expo on Vaccines & Immunology

Montreal, Canada
September 09-10, 2024

4th International Conference on Vaccine Research

Madrid, Spain
November 28-29, 2024

6th World Congress on Vaccine and Immunology

Paris, France

Cancer, Malaria & TB Vaccines Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in